TY - JOUR
AU - Holt S.
AU - Wang A.
AU - Johnson D.
AU - Jha V.
AU - Brimble K.
AU - Brunier G.
AU - Kang S.
AU - Kooman J.
AU - Lambie M.
AU - McIntyre C.
AU - Mehrotra R.
AU - Pecoits-Filho R.
AB - <p>
Cardiovascular disease contributes significantly to the adverse clinical outcomes of peritoneal dialysis (PD) patients. Numerous cardiovascular risk factors play important roles in the development of various cardiovascular complications. Of these, loss of residual renal function is regarded as one of the key cardiovascular risk factors and is associated with an increased mortality and cardiovascular death. It is also recognized that PD solutions may incur significant adverse metabolic effects in PD patients. The International Society for Peritoneal Dialysis (ISPD) commissioned a global workgroup in 2012 to formulate a series of recommendations regarding lifestyle modification, assessment and management of various cardiovascular risk factors, as well as management of the various cardiovascular complications including coronary artery disease, heart failure, arrhythmia (specifically atrial fibrillation), cerebrovascular disease, peripheral arterial disease and sudden cardiac death, to be published in 2 guideline documents. This publication forms the first part of the guideline documents and includes recommendations on assessment and management of various cardiovascular risk factors. The documents are intended to serve as a global clinical practice guideline for clinicians who look after PD patients. The ISPD workgroup also identifies areas where evidence is lacking and further research is needed.
</p>

AD - Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong aymwang@hkucc.hku.hk.<br/>St. Joseph's Healthcare, McMaster University, Hamilton, Ontario, Canada.<br/>Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.<br/>Division of Nephrology, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.<br/>George Institute for Global Health India, Postgraduate Institute of Medical Education and Research, Chandigarh, India.<br/>University of Queensland at Princess Alexandra Hospital, Brisbane, Australia Centre for Kidney Disease Research, Translational Research Institute, Brisbane, Australia.<br/>Department of Internal Medicine, College of Medicine, Severance Biomedical Science Institute, Yonsei University, Korea.<br/>Division of Nephrology, University Hospital Maastricht, Maastricht, The Netherlands.<br/>Health Services Research Unit, Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, United Kingdom.<br/>School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby, United Kingdom.<br/>Harborview Medical Center, Division of Nephrology/Department of Medicine, University of Washington, Washington, DC, United States.<br/>School of Medicine, Pontificia Universidade Catolica do Parana, Curitiba, Parana, Brazil.
AN - 26228782
BT - Peritoneal Dialysis International
DP - NLM
ET - 2015/08/01
LA - Eng
LB - INDIA
M1 - 4
N1 - Wang, Angela Yee Moon<br/>Brimble, K Scott<br/>Brunier, Gillian<br/>Holt, Stephen G<br/>Jha, Vivekanand<br/>Johnson, David W<br/>Kang, Shin-Wook<br/>Kooman, Jeroen P<br/>Lambie, Mark<br/>McIntyre, Chris<br/>Mehrotra, Rajnish<br/>Pecoits-Filho, Roberto<br/>Perit Dial Int. 2015 7-8;35(4):379-387.
N2 - <p>
Cardiovascular disease contributes significantly to the adverse clinical outcomes of peritoneal dialysis (PD) patients. Numerous cardiovascular risk factors play important roles in the development of various cardiovascular complications. Of these, loss of residual renal function is regarded as one of the key cardiovascular risk factors and is associated with an increased mortality and cardiovascular death. It is also recognized that PD solutions may incur significant adverse metabolic effects in PD patients. The International Society for Peritoneal Dialysis (ISPD) commissioned a global workgroup in 2012 to formulate a series of recommendations regarding lifestyle modification, assessment and management of various cardiovascular risk factors, as well as management of the various cardiovascular complications including coronary artery disease, heart failure, arrhythmia (specifically atrial fibrillation), cerebrovascular disease, peripheral arterial disease and sudden cardiac death, to be published in 2 guideline documents. This publication forms the first part of the guideline documents and includes recommendations on assessment and management of various cardiovascular risk factors. The documents are intended to serve as a global clinical practice guideline for clinicians who look after PD patients. The ISPD workgroup also identifies areas where evidence is lacking and further research is needed.
</p>

PY - 2015
SN - 1718-4304 (Electronic)<br/>0896-8608 (Linking)
SP - 379
EP - 387
T2 - Peritoneal Dialysis International
TI - ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I - Assessment and Management of Various Cardiovascular Risk Factors
VL - 35
Y2 - FY16
ER -